Insulet announced that its Omnipod 5 automated insulin delivery (AID) system is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S.

The company said Omnipod 5 simplifies diabetes management and has shown to improve results by removing the necessity for multiple daily injections (MDI) therapy and automatically adjusting insulin delivery every five minutes via its SmartAdjust technology.

Omnipod 5 is the first tubeless AID system that communicates with a CGM, proactively correcting for highs and helping protect against lows. It was rolled out in the U.S. with Dexcom G7 compatibility in June 2024.

Omnipod 5 user John Rowley, who lives in the UK where the FreeStyle Libre 2 Plus sensor integration launched earlier this year, had been using MDI for 36 years before making the switch to Pod therapy.

“Having spent more than half my life injecting myself with insulin, Omnipod 5 with its connection to my FreeStyle Libre 2 Plus sensor has been truly liberating. When you have diabetes, there is so much more to think about when it comes to daily life,” said Mr. Rowley. “Omnipod 5 has made my life so much simpler, with much less to carry around with me, and less to worry about overall.”

In August, Omnipod 5 received U.S. Food and Drug Administration (FDA) clearance that extended it to adults with type 2 diabetes, as well.

“We are excited to announce that Omnipod 5, the only AID system indicated for both type 1 and type 2 diabetes, is now integrated with Abbott’s FreeStyle Libre 2 Plus sensor in the U.S. This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod therapy using their preferred CGM sensor,” said Eric Benjamin, Insulet’s executive VP and chief product and customer experience officer. “As we work to reach more people with our innovative, tubeless Omnipod 5 AID System, today’s announcement represents yet another significant step forward for our Company and our customers.”